You are here:

Ocrelizumab (Ocrevus) for primary progressive MS - help us make the case to NICE

Published on

NICE is assessing ocrelizumab for primary progressive MS (PPMS) to decide whether it should be prescribed by the NHS in England and Wales.  Scotland and Northern Ireland will carry out separate appraisals.

The MS Trust will be explaining to NICE why we think ocrelizumab should be made available on the NHS. To help us make a strong case, we want to hear your experiences of living with PPMS, your views on current NHS care for PPMS and your thoughts on ocrelizumab.

We’d like to hear from you if

  • you have primary progressive MS
  • you have a different type of MS, but would like to add your views
  • you are a partner / friend / relative / carer of someone with PPMS
  • you are a health professional providing care for people with PPMS

Tell us what you think by completing this short questionnaire  by 14 February.

Print this page